OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).

被引：0
|
作者：
Tsakiridis, Theodoros
Gouveia, Andre
Mesci, Aruz
Vavassis, Peter
Berlin, Alejandro
Morgan, Scott C.
Perlis, Nathan
Niazi, Tamim
Thoms, John
Hotte, Sebastien J.
Wright, Jim
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Hamilton Hlth Sci, Juravinski Canc Ctr, Radiat Oncol, Hamilton, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Hop Maisonneuve Rosemont Montreal, Montreal, PQ, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Canc Digital Intelligence, Toronto, ON, Canada
[8] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[9] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol,Div Urol, Toronto, ON, Canada
[10] McGill Univ, Montreal, PQ, Canada
[11] Mem Univ, St John, NF, Canada
[12] McMaster Univ, Juravinski Canc Inst, Hamilton, ON, Canada
[13] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.TPS305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS305 / TPS305
页数：1
相关论文
共 33 条
  • [1] PHASE II RANDOMIZED TRIAL OF OPTIMAL RECURRENCE-DIRECTED THERAPY (RDT) WITHOUT OR WITH ANDROGEN-DEPRIVATION THERAPY (ADT) IN RADIO-RECURRENT OLIGO-METASTATIC HORMONE/CASTRATE SENSITIVE PROSTATE CANCER (ROMCSPC): THE OCOG-RATIONAL-PCS TRIAL
    Gouveia, Andre
    Vavassis, Peter
    Mesci, Aruz
    Hotte, Sebastien
    Berlin, Alejandro
    Zukotynski, Katherine
    Morgan, Scott
    Dayes, Ian
    Perlis, Nathan
    Wright, Jim
    Pond, Gregory
    Niazi, Tamim
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S54 - S55
  • [2] Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC)
    Antonarakis, Emmanuel S.
    Kibel, Adam
    Tyler, Robert Claude
    McCoy, Candice
    Wang, Yang
    Sheikh, Nadeem A.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
    Burgess, Earle Frederick
    Grigg, Claud
    Clark, Peter E.
    Boselli, Danielle
    Symanowski, James Thomas
    Raghavan, Derek
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.
    Maluf, Fernando Cotait
    Soares, Andrey
    Bastos, Diogo Assed
    Schutz, Fabio A. B.
    Cronemberger, Eduardo
    Luz, Murilo
    Martins, Suelen P. S.
    Muniz, David Queiroz Borges
    Carcano, Flavio Mavignier
    Smaletz, Oren
    Peixoto, Abio A.
    Gomes, Andrea J.
    Cruz, Felipe Melo
    Franke, Fabio
    Herchenhorn, Daniel
    Gidekel, Rosemarie
    Rebelatto, Taiane Francieli
    Gomes, Rafaela
    Souza, Vinicius Carrera
    Fay, Andre P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
    Saad, F.
    Vjaters, E.
    Shore, N. D.
    Olmos, D.
    Xing, N.
    Gomes, A. J. P. D. S.
    Mota, A. C. A.
    Salman, P.
    Jievaltas, M.
    Ulys, A.
    Jakubovskis, M.
    Kopyltsov, E.
    Han, W.
    Nevalaita, L.
    Testa, I.
    Le Berre, M-A.
    Kuss, I.
    Kunhiparambath, H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1257 - 1258
  • [6] A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
    Palmbos, Phillip L.
    Daignault-Newton, Stephanie
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia K.
    Kelly, Wm. Kevin
    Arora, Vivek K.
    Antonarakis, Emmanuel S.
    Siddiqui, Javed
    Jacobson, Jon A.
    Davenport, Matthew S.
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    Knudsen, Karen E.
    Hussain, Maha
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3017 - 3027
  • [7] A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
    McKay, Rana R.
    Zurita, Amado J.
    Werner, Lillian
    Bruce, Justine Y.
    Carducci, Michael A.
    Stein, Mark N.
    Heath, Elisabeth I.
    Hussain, Arif
    Tran, Hai T.
    Sweeney, Christopher J.
    Ross, Robert W.
    Kantoff, Philip W.
    Slovin, Susan F.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1913 - +
  • [8] Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.
    Zurita, Amado J.
    Tidwell, Rebecca Slack
    Troncoso, Patricia
    Chapin, Brian Francis
    Harris, Deborah
    Pisters, Louis L.
    Araujo, John C.
    Pettaway, Curtis Alvin
    Aparicio, Ana
    Tu, Shi-Ming
    Papadopoulos, John N.
    Wang, Jennifer
    Logothetis, Christopher
    Pagliaro, Lance C.
    Davis, John W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results
    Antonarakis, Emmanuel S.
    Kibel, Adam S.
    Adams, George
    Karsh, Lawrence Ivan
    Elfiky, Aymen
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Corman, John M.
    Tyler, Robert Claude
    Mccoy, Candice
    Wang, Yang
    Sheikh, Nadeem A.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
    Antonarakis, Emmanuel S.
    Kibel, Adam S.
    Yu, Evan Y.
    Karsh, Lawrence I.
    Elfiky, Aymen
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Corman, John M.
    Millard, Frederick E.
    Maher, Johnathan C.
    Chang, Nancy N.
    DeVries, Todd
    Sheikh, Nadeem A.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2451 - 2459
1234